A Phase 1b/2a proof-of-concept study for plamotamab in multi-drug resistant rheumatoid arthritis (MDR-RA)
Latest Information Update: 11 Sep 2024
At a glance
- Drugs Plamotamab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacodynamics; Proof of concept; Therapeutic Use
- 11 Sep 2024 New trial record
- 09 Sep 2024 According to a Xencor media release, company plans to initiate a Phase 1b/2a proof-of-concept study for plamotamab in MDR-RA in the first half of 2025.